F10 and atrial fibrillation: To compare edoxaban with warfarin in the peri-cardioversion setting, a post hoc analysis of ENGAGE AF-TIMI 48 (the Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48) trial evaluated outcomes of 365 patients (632 ECV attempts) undergoing ECV on average 348 days post-randomization.